ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Modification of Donor Tissue Antigens with Papain To Inhibit Transplant Rejection

D. Faustman

Immunobiology Laboratory, Massachusetts General Hospital &
Harvard Medical, Charlestown, MA

Meeting: 2013 American Transplant Congress

Abstract number: B957

PURPOSE: The development of novel drugs to hinder transplant rejection is expensive, time consuming and inevitably exposes the subject to lifelong immunosuppression. In contrast, modifying in vitro the donor transplant antigens on donor cells/organ/tissues prior to surgery is an attractive way to thwart host recognition. The purpose of this study was to investigate a simple, in vitro, enzyme-based method to cleave off donor MHC/HLA class I proteins, the dominant trigger of graft rejection, from donor cells to inhibit the host rejection response.

METHODS: Papain in modified physiological pH buffers was used to temporarily ablate MHC class I antigens on murine cells in culture. Ablation of class I structures was confirmed by flow cytometry prior to transplantation of the modified allografts in chemically induced diabetic mice and in a mouse model of liver transplantation. Untreated, secondary allogeneic transplants were later performed in the same host.

RESULTS: At the end of a brief treatment period, all cells remained fully viable and were void of class I surface structures. Transient removal of class I with papain prolonged graft survival. Re-synthesis of MHC class I induced graft-specific tolerance also allowed unprotected, fully allogeneic secondary transplants to be successfully performed in the same host, with prolonged transplant survival in the form of insulin secreting islets or liver cells.

CONCLUSIONS: The enzyme papain is able to rapidly cleave diverse MHC class I alleles from the surface of animal and human cells. Transient or even partial ablation of donor MHC class I using enzymes was sufficient for long-term survival of transplanted cells. An enzyme-based, in vitro donor antigen modification technique may be a new approach to inducing transplant tolerance. Indeed, such simple approaches of donor antigen modification could expand the use of diverse cell transplantation therapies into diseases where high dose immunosuppressive regimens may not be justified.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Faustman D. Modification of Donor Tissue Antigens with Papain To Inhibit Transplant Rejection [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/modification-of-donor-tissue-antigens-with-papain-to-inhibit-transplant-rejection/. Accessed May 17, 2025.

« Back to 2013 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences